MX2021014116A - Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). - Google Patents
Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).Info
- Publication number
- MX2021014116A MX2021014116A MX2021014116A MX2021014116A MX2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- inhibitors
- relates
- pyridopyrimidines
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula I que inhiben el purinoreceptor 3 de P2X (en lo sucesivo inhibidores de P2X3); la invención se refiere particularmente a compuestos que son derivados de piridopirimidinas, métodos para preparar estos compuestos, composiciones farmacéuticas que los contienen y uso terapéutico de los mismos. Los compuestos de la invención pueden ser útiles en el tratamiento de muchos trastornos asociados con mecanismos de los receptores P2X3, tales como enfermedades respiratorias que incluyen tos, asma, fibrosis pulmonar idiopática (IPF) y enfermedad pulmonar obstructiva crónica (COPD).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19177610 | 2019-05-31 | ||
EP19201165 | 2019-10-02 | ||
PCT/EP2020/064915 WO2020239953A1 (en) | 2019-05-31 | 2020-05-28 | Pyridopyrimidines derivatives as p2x3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014116A true MX2021014116A (es) | 2021-12-10 |
Family
ID=70857198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014116A MX2021014116A (es) | 2019-05-31 | 2020-05-28 | Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230212169A9 (es) |
EP (1) | EP3976609A1 (es) |
JP (1) | JP2022534434A (es) |
KR (1) | KR20220016074A (es) |
CN (1) | CN114222741A (es) |
AU (1) | AU2020281924A1 (es) |
BR (1) | BR112021020279A2 (es) |
CA (1) | CA3136024A1 (es) |
MA (1) | MA56020A (es) |
MX (1) | MX2021014116A (es) |
WO (1) | WO2020239953A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022160931A1 (zh) * | 2021-01-28 | 2022-08-04 | 浙江海正药业股份有限公司 | 吡啶并嘧啶类衍生物及其制备方法和用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4342007B2 (ja) * | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
ES2439454T3 (es) * | 2005-09-01 | 2014-01-23 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores de P2X3 y P2X2/3 |
BR122019017036B8 (pt) | 2006-06-29 | 2021-07-27 | Hoffmann La Roche | compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica |
JP5396379B2 (ja) * | 2007-04-02 | 2014-01-22 | エボテック・アーゲー | ピリド−2−イル縮合複素環式化合物ならびにその組成物および使用 |
WO2008130481A1 (en) | 2007-04-17 | 2008-10-30 | Renovis, Inc. | 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof |
CA2715835C (en) | 2008-02-29 | 2017-03-21 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
JP5608655B2 (ja) | 2008-09-18 | 2014-10-15 | エヴォテック アーゲー | P2x3受容体活性のモジュレーター |
WO2011041655A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Quinazolin-4-amine derivatives; and methods of use |
US8901133B2 (en) * | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2016084922A1 (ja) | 2014-11-28 | 2016-06-02 | 塩野義製薬株式会社 | 1,2,4-トリアジン誘導体およびその医薬組成物 |
WO2016088838A1 (ja) | 2014-12-04 | 2016-06-09 | 塩野義製薬株式会社 | プリン誘導体およびその医薬組成物 |
SI3587417T1 (sl) | 2014-12-09 | 2022-04-29 | Bayer Ag | 1,3-tiazol-2-il substituirani benzamidi |
WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
AU2016330466B2 (en) | 2015-09-29 | 2021-01-28 | Afferent Pharmaceuticals, Inc. | Diaminopyrimidine P2x3 and P2x2/3 receptor modulators for use in the treatment of cough |
CA3006300C (en) * | 2015-11-25 | 2024-02-27 | Convergene Llc | Bicyclic bet bromodomain inhibitors and uses thereof |
GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
EA202190339A1 (ru) * | 2018-07-25 | 2021-05-20 | Фаэс Фарма, С.А. | Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов |
-
2020
- 2020-05-28 CN CN202080038831.1A patent/CN114222741A/zh active Pending
- 2020-05-28 KR KR1020217038473A patent/KR20220016074A/ko unknown
- 2020-05-28 JP JP2021571021A patent/JP2022534434A/ja active Pending
- 2020-05-28 BR BR112021020279A patent/BR112021020279A2/pt unknown
- 2020-05-28 MA MA056020A patent/MA56020A/fr unknown
- 2020-05-28 EP EP20728500.8A patent/EP3976609A1/en active Pending
- 2020-05-28 US US17/615,012 patent/US20230212169A9/en active Pending
- 2020-05-28 WO PCT/EP2020/064915 patent/WO2020239953A1/en unknown
- 2020-05-28 CA CA3136024A patent/CA3136024A1/en active Pending
- 2020-05-28 AU AU2020281924A patent/AU2020281924A1/en active Pending
- 2020-05-28 MX MX2021014116A patent/MX2021014116A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230212169A9 (en) | 2023-07-06 |
KR20220016074A (ko) | 2022-02-08 |
MA56020A (fr) | 2022-04-06 |
CA3136024A1 (en) | 2020-12-03 |
JP2022534434A (ja) | 2022-07-29 |
EP3976609A1 (en) | 2022-04-06 |
BR112021020279A2 (pt) | 2021-12-14 |
US20220235060A1 (en) | 2022-07-28 |
AU2020281924A1 (en) | 2021-12-16 |
CN114222741A (zh) | 2022-03-22 |
WO2020239953A1 (en) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014113A (es) | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
SA519402319B1 (ar) | Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز | |
MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
PH12016501439A1 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
MX2020012202A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilizacion de fibras nerviosas. | |
MX2021000270A (es) | Derivados de la tirosina amida como inhibidores de la rho- cinasa. | |
MX2018008439A (es) | Orvepitant para el tratamiento de la tos cronica. | |
WO2016168553A8 (en) | Deuterated obeticholic acid | |
MX2022013014A (es) | Nuevas formas cristalinas de trifenatato de vilanterol y procedimientos para su preparacion. | |
MX2021014116A (es) | Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
MX2023005805A (es) | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
MX2023005801A (es) | Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3). | |
MX368036B (es) | Particulas inhalables que comprenden tiotropio e indacaterol. | |
MX2023005803A (es) | Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
MX2007011079A (es) | Derivados de diaza-espiro-[4-4]-nonano como antagonistas de la neurocinina (nk1). | |
MX2021015553A (es) | Inhibidores de arginasa novedosos. | |
EA202193300A1 (ru) | Производные аминохиназолина в качестве p2x3 ингибиторов | |
MX2023005867A (es) | Derivados de dihidrofuropiridina como inhibidores de la cinasa rho. | |
MX2023005865A (es) | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. | |
MX2023005866A (es) | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. | |
MX2020011472A (es) | Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide. | |
MX2022004809A (es) | Composiciones para prevenir o tratar enfermedad pulmonar obstructiva cronica (epoc). | |
NZ761390A (en) | Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor | |
TR201720845A1 (tr) | Oral farmasöti̇k terki̇pler | |
TR201716209A2 (tr) | Arformoterol ve umeklidinyum içeren yeni farmasötik bileşimler. |